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Purpose: To report the ﬁnal 2-year data on the efﬁcacy and safety of a nitinol retrievable inferior vena cava (IVC) ﬁlter for
protection against pulmonary embolism (PE).
Materials and Methods: This was a prospective multicenter trial of 200 patients with temporary indications for caval ﬁltration
who underwent implantation of the Denali IVC ﬁlter. After ﬁlter placement, all patients were followed for 2 years after
placement or 30 days after ﬁlter retrieval. The primary endpoints were technical success of ﬁlter implantation in the intended
location and clinical success of ﬁlter placement and retrieval. Secondary endpoints were incidence of clinically symptomatic
recurrent PE, new or propagating deep vein thrombosis (DVT), and ﬁlter-related complications including migration, fracture,
penetration, and tilt.
Results: Filter placement was technically successful in 199 patients (99.5%). Filters were clinically successful in 190 patients
(95%). The rate of PE was 3% (n ¼ 6), with 5 patients having a small subsegmental PE and 1 having a lobar PE. New or
worsening DVT was noted in 26 patients (13%). Filter retrieval was attempted 125 times in 124 patients and was technically
successful in 121 patients (97.6%). The mean ﬁlter dwell time at retrieval was 200.8 days (range, 5–736 d). There were no
instances of ﬁlter fracture, migration, or tilt greater than 151 at the time of ﬁlter retrieval or during follow-up.
Conclusions: The Denali IVC ﬁlter exhibited high success rates for ﬁlter placement and retrieval while maintaining a low
complication rate in this clinical trial.
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Stavropoulos et al ’ JVIR1532 ’ Analysis of Final DENALI IVC Filter Trial DataInferior vena cava (IVC) ﬁlters can provide efﬁcacious
prophylaxis against pulmonary embolism (PE) in appro-
priately selected patients (1,2), as reﬂected by current
consensus guidelines from the American College of
Chest Physicians (3) and Society of Interventional
Radiology (SIR) (4). The DENALI study was con-
ducted to evaluate the safety, clinical efﬁcacy, and
technical efﬁcacy of the Denali retrievable vena cava
ﬁlter (Bard Peripheral Vascular, Tempe, Arizona). An
interim analysis of the data from the study (5) revealed
clinical success in 94.5% of cases (lower limit of 95%
conﬁdence interval [CI], 90.1%) in the setting of a 3%
incidence of recurrent PE. Technical success rates were
99.5% for ﬁlter placement and 97.3% for ﬁlter retrieval
(5). No cases of ﬁlter fracture, migration, or tilt 4 151
were reported in this interim analysis (5). Two hundred
patients had been enrolled in the interim report, but full
follow-up had not been completed in all patients. The
present study reports the ﬁnal analysis for the DENALI
study with completed 24-month clinical follow-up.MATERIALS AND METHODS
A detailed description of the DENALI trial design,
inclusion and exclusion criteria, and interim outcomes
was previously reported (5). The trial was a prospective,
multicenter, nonrandomized, single-arm study con-
ducted at 21 centers in the United States to assess safety,
technical success, and clinical success of placement and
retrieval of the Denali vena cava ﬁlter. Patients eligible
for inclusion in the study had documented evidence of
thromboembolic disease (deep vein thrombosis [DVT] or
PE) at the time of ﬁlter placement or were at temporary
risk of PE with a clinical need for vena cava interrup-
tion. The institutional review board of each participating
institution approved the study, and all procedures were
conducted in accordance with the Health Insurance
Portability and Accountability Act. Bard Peripheral
Vascular was the sole sponsor of this Investigational
Device Exemption study; the protocol was reviewed and
approved by the US Food and Drug Administration
(FDA) before the start of patient enrollment. Data were
collected on electronic case report forms and processed
with a Web-based data management system. The Yale
Cardiovascular Research Group (New Haven, Connect-
icut) provided independent core laboratory analysis of
implant and retrieval vena cavograms and radiographs,
with the reader having 20 years of postfellowship
experience. An independent clinical events committee
(CEC) reviewed and adjudicated all adverse events, an
independent physician medical monitor reviewed device
observations for trends or unanticipated events, and an
independent data safety monitoring board reviewed
safety information from individual investigators and
the CEC to determine whether the study should con-
tinue, stop, or change. The DENALI trial was registeredbefore the start of patient enrollment (ClinicalTrials.gov
ID NCT01305564).
Study Endpoints
The primary objectives of the DENALI study were to
assess the technical and clinical success of ﬁlter place-
ment and retrieval. Patients were followed for 2 years
after ﬁlter placement to assess long-term ﬁlter implanta-
tion or for 1 month after ﬁlter retrieval to assess safety
and efﬁcacy of device removal. Primary endpoints at
ﬁlter placement included technical success of ﬁlter place-
ment, deﬁned as sufﬁcient mechanical interruption in the
vena cava to prevent PE, and clinical success of ﬁlter
placement, a composite endpoint that included freedom
from subsequent PE, ﬁlter migration, vena cava occlu-
sion, ﬁlter- or procedure-related death, adverse events
associated with ﬁlter placement, or failure of ﬁlter
placement. Per protocol, and in line with SIR guidelines,
clinical success was achieved if the lower bound of the
95% CI was 4 80% (4,6–9). Technical success of ﬁlter
retrieval was achieved if the ﬁlter was retrieved intact
without immediate complications, and clinical success of
ﬁlter retrieval was achieved if the ﬁlter was retrieved
without complications requiring intervention.
Secondary outcomes included recurrent PE, new or
worsening DVT, and postimplantation ﬁlter issues such
as fracture, migration, penetration, and tilt. Assessment
of ﬁlter issues was based on the American College of
Radiology and SIR guidelines (4,6–9). Recurrent PE
(ie, PE occurring after ﬁlter placement) was assessed by
pulmonary arteriography, cross-sectional imaging,
altered ventilation/perfusion lung scan, or autopsy in
all patients implanted with a ﬁlter regardless of the
duration of follow-up. New DVT was deﬁned as an
image-based report of DVT in patients who did not have
DVT at baseline, and worsening DVT was deﬁned as
extension of existing DVT to a new venous segment,
based on imaging, in patients who had DVT at the
baseline visit. The core laboratory assessed postplace-
ment, follow-up, and preretrieval images (conventional
radiographs, computed tomography [CT] scans, or veno-
grams) for evidence of structural loss, broken or sepa-
rated ﬁlter components (ie, ﬁlter fracture), change in
ﬁlter position of more than 2 cm cranial or caudal
compared with the baseline deployed position (ie, migra-
tion), evidence of ﬁlter leg or arm penetrating outside of
the IVC wall by more than 3 mm, and ﬁlter tilt of more
than 151 off the axis of the IVC. Finally, adverse events,
deﬁned as any untoward medical occurrence, were
reported by the study investigators and reviewed and
adjudicated by the CEC.
Study Device and Interventions
Details of the device and procedure were previously
published (5). Patients who met the criteria for study
enrollment received an optional Denali IVC ﬁlter.
Table 1 . Baseline Demographics
Characteristic
All Patients
(N ¼ 200)
Retrieved Filter
(n ¼ 121)
Sex
Male 126 (63) 80 (67.8)
Female 74 (37) 41 (32.2)
Mean age (y) 56.6  15.63 55.9  14.64
Weight (kg) 97.4  26.0 99.9  25.5
BMI (kg/m2) 32.9  9.07 33.8  9.23
Race
White 164 (82.0) 103 (85.1)
Black 31 (15.5) 15 (12.4)
Native American 1 (0.5) 0
Other 4 (2.0) 3 (2.5)
Note–Values presented as mean  standard deviation where
applicable. Values in parentheses are percentages.
BMI ¼ body mass index.
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imaging was completed to conﬁrm or rule out the
presence of lower-extremity DVT. Pre- and postplace-
ment imaging was performed to establish baseline ﬁlter
position for primary and secondary endpoint assess-
ments. All images were reviewed by two independent
readers at the Yale Core Laboratory. A follow-up clinic
visit was performed 6 months after placement, at which
time an abdominal radiograph was obtained to evaluate
IVC ﬁlter position compared with baseline and a US
examination of the deep veins of the legs was performed.
Phone consultations with the patient were completed at
3, 12, 18, and 24 months after the procedure to deter-
mine whether the patient experienced ﬁlter-related symp-
tomatic complications. A loop snare was used to engage
the ﬁlter hook located on the apex of the device and
remove the ﬁlter. Anteroposterior and lateral digital
subtraction vena cavograms were obtained just before
ﬁlter retrieval, with a ﬁnal vena cavogram obtained
immediately after retrieval. Patients were evaluated in
the clinic at 30 days after ﬁlter retrieval to assess overall
health status and the recurrence of PE or DVT and to
document any ﬁlter-related complications.Statistical Analysis
SIR reporting standards were used when applicable to
evaluate results (7). Endpoints were analyzed per patient
on an intent-to-treat basis. All patients enrolled in the
study were followed until 24 months after ﬁlter place-
ment or 30 days after ﬁlter retrieval. Continuous
variables were described as a mean  standard devia-
tion, and categoric variables were described as counts
and percentages. Primary endpoints were summarized
descriptively and reported as estimated proportions with
associated 95% CIs. The lower 95% CI for the observed
clinical success rate was used as a measure of success
(per SIR guidelines); if it was greater than or equal to
80%, it was concluded that the endpoint was successfully
achieved (4,6).RESULTS
Investigators at 21 sites enrolled 200 patients, 60% with
active venous thromboembolic disease (DVT, n = 59,
PE, n = 23; both, n = 38) at the time of ﬁlter placement
and the remainder (40%) with temporary increased
risk of PE requiring IVC interruption (ie, prophylactic
placement with no documented evidence of active
thromboembolic disease). The patient population
was described in a previous publication (5) and is
summarized in Table 1. The ﬁlters were implanted
percutaneously through a femoral vein in 128 patients
(64%) and through a jugular/subclavian vein in 72
patients (36%). The mean IVC diameter at placement
was 22.2 mm  3.1, with a range of 12.7–27.8 mm.Filter placement was technically successful in 99.5% of
patients (n ¼ 199; 95% CI, 97.3%–100%; Table 2). One
ﬁlter could not be deployed out of the delivery sheath,
resulting in a technical failure. The delivery sheath and
undeployed device were removed; a new ﬁlter was then
placed in the IVC without incident and was subsequently
retrieved at 630 days with no reported complications.
Three additional ﬁlters (1.5%) were not placed in the
exact location intended by the operator. They
were successfully deployed in the infrarenal IVC, and
were not classiﬁed as technical failures because they were
placed within 1 cm of the intended location within the
infrarenal IVC. One of the three ﬁlters was inadvertently
moved caudally 1 cm by a guide wire after deployment,
and two ﬁlters were deployed approximately 10 mm
caudal to the desired location in the vena cava. The
operator decided to remove and replace the device that
was accidentally moved with the guide wire; the patient
was followed up for 24 months, and no complications
were reported. The other two ﬁlters were left in situ; one
was subsequently successfully retrieved 95 days after the
placement procedure and the other remained implanted
at the end of the study with no reported clinical sequelae.
Clinical success of placement was achieved in 95.0% of
patients (n ¼ 190; 95% CI, 91.0%–97.6%; Table 2).
Including the previously noted technical failure (one
event), nine additional patients met criteria for clinical
failure as a result of 11 events: recurrent PE (seven
events), caval occlusion (one event), and access-related
bruising or discomfort without further clinical sequelae
(three events). The CEC adjudicated ﬁve clinical failures
as possibly related to the device and two of the access
complications as related to the procedure. One patient
who had the ﬁlter placed because of active thromboem-
bolic disease experienced three of the events: two new
PEs after placement (at 57 and 127 d) and one caval
occlusion treated with thrombolysis and venoplasty.
Overall clinical success of placement was achieved per
Table 2 . Placement Procedures in All Patients (N ¼ 200)
Variable Value
Placement procedural data
Placement time (min)
Mean  SD 17.8  10.32
Median 17
Range 3–90
Fluoroscopy time (min)
Mean  SD 3.6  3.14
Median 3.0
Range 1–32
IVC diameter (mm)*
Mean  SD 22.2  3.10
Median 22.5
Range 12.7–27.8
Vascular access sites
Right common femoral vein 110 (55.0)
Right jugular vein 70 (35.0)
Left common femoral vein 18 (9.0)
Left jugular vein 2 (1.0)
Hospitalization status
Inpatient 160 (80.0)
Outpatient 40 (20.0)
Placement success
Technical success of placement† 199 (99.5)
95% CI 97.3–100
Clinical success of placement‡ 190 (95.0)
95% CI 91.0–97.6
Recurrence of PE§ 6 (3.0)
Filter embolization 0
Filter-/procedure-related death 0
Insertion adverse event 3 (1.5)
Technical failure 1 (1.0)
Note–Values in parentheses are percentages.
SD ¼ standard deviation.
*Quantitatively measured by the core laboratory before ﬁlter
placement.
†One ﬁlter was introduced but could not be deployed. A
second ﬁlter was successfully deployed in the patient without
clinical sequelae.
‡The intent-to-treat population consisted of 200 patients, of
whom 190 had clinical success of ﬁlter placement.
§There were 12 events in 10 patients. One patient had three
events (two new pulmonary emboli and one caval occlusion).
Stavropoulos et al ’ JVIR1534 ’ Analysis of Final DENALI IVC Filter Trial Datathe study protocol, as the lower bound of the 95% CI
(91%) was greater than 80%.
Postprocedure Follow-up
Patients were followed up as part of the study for 24
months or for 30 days after ﬁlter retrieval (Fig 1).
Overall, 37 patients did not complete the trial; 21 died
from causes unrelated to the IVC ﬁlter or placement
procedure, four patients withdrew or were removed at
the discretion of an investigator, and 12 were lost to
follow-up. Filter retrieval did not occur in 76 patients, 43
of whom completed the 24-month follow-up.Filter Retrieval
One hundred thirty patients at 19 sites were screened
with a venogram for ﬁlter removal. Five procedures were
aborted after the diagnostic venogram at the discretion
of the operator because the thrombus burden in the ﬁlter
was believed to be too large to allow safe removal of the
device (ie, a retrieval attempt was not begun). All ﬁve
patients were subsequently treated with anticoagulation
and returned for another screening venogram. In each of
these cases, the second venogram revealed no signiﬁcant
thrombus, and the ﬁlters were successfully removed.
Filter retrieval was attempted 125 times in 124 patients
(one patient had two retrieval attempts, with the second
accomplished successfully); 121 ﬁlters were successfully
retrieved, resulting in a retrieval technical success rate of
97.6% (121 of 124 patients; 95% CI, 93.1%–99.5%;
Table 3). The median procedure time was 20 minutes
(range, 4–118 min). Three retrieval attempts failed: in
two cases, the ﬁlter apex could not be engaged because
of the anatomic curvature of the IVC, and, in one case,
the ﬁlter contained clot, causing the physician to be
unable to collapse the ﬁlter. Of the 121 patients with
successful ﬁlter retrievals, 120 had their ﬁlters retrieved
without complication requiring intervention (99.2%
clinical success of retrieval). The one patient with a
complication experienced asymptomatic intimal injury
and caval narrowing after retrieval and was admitted
overnight for observation (Table 3). No further inter-
ventions or hospitalizations were required.
Filter retrieval was performed in nearly equal propor-
tions of patients who had ﬁlter placement for active
thromboembolic disease (50.4%) and for PE prophylaxis
(49.6%). The mean dwell time was 200.8 days (range,
5–736 d; Table 3). Fifty-six ﬁlters (46.3%) were retrieved
4 6 months after implantation, 20 of which were
retrieved at more than 1 year, with no ﬁlter-related
issues reported (ie, no migration, penetration, tilt, or
retrieval complications; Fig 2). One-month follow-up
evaluations were completed by 119 patients who had
their ﬁlters retrieved (two patients were lost to follow-up
before the 30-d evaluation). None of the patients
had symptomatic recurrent PE or symptomatic new or
worsening DVT after retrieval. At the 1-month assess-
ment, the use of anticoagulant agents was reported in
40.3% of patients (48 of 119).Secondary Outcomes
Rates of PE, new or worsening DVT, ﬁlter fracture,
migration (4 2 cm), penetration (4 3 mm), and tilt
(4 151) are presented in Table 4. On ﬁnal analysis, the
rate of PE was 3.0% (6 of 200; 95% CI, 1.1%–6.4%).
Five of these patients had small recurrent PEs with-
out high-risk symptoms. A more proximal lobar PE
developed in one patient with advanced malignancy, in
addition to hypotension and right ventricular dysfunc-
tion, and the patient subsequently died, presumably as a
Figure 1. Disposition of the 200 patients in the DENALI study. Filters were successfully retrieved in 121 patients, 119 of whom were
followed for 30 days after retrieval. The ﬁlter remained implanted in 76 patients, 43 of whom completed 2-year follow-up.
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course of the study, 28 cases of new or worsening
DVT were reported in 26 patients: 18 patients (9.0%)
without baseline DVT showed the development of new
DVT and eight patients (4.0%) with baseline DVT
showed the development of thrombus extension into a
new venous segment.
All implant, retrieval, and 6-month images were
independently analyzed by the Yale Core Laboratory
and assessed by the study investigators for ﬁlter fracture,
migration, penetration, and tilt (Table 4). The core
laboratory found no evidence of ﬁlter fracture,
migration greater than 2 cm, or tilt greater than 151 in
any case. Notably, investigators reported ﬁlter tilt4 151
in one case at placement and two cases at retrieval, but
subsequent quantiﬁcation by the core laboratory
revealed tilt o 151. The core laboratory reported three
cases of penetration greater than 3 mm at ﬁlter
placement (1.5%; 95% CI, 0.3%–4.3%) and two at
retrieval (two of 124; 1.6%; 95% CI, 0.2%–5.7%). After
retrieval, there was one case of minimal extraluminal
contrast agent extravasation, which was asymptomatic
and self-resolved without necessitating admission or further
intervention. The caval penetrations were asymptomatic.Safety
One or more adverse events were observed during the
course of the study in 160 patients, of whom 90 patients
had one or more serious adverse event, the most
common of which was infection (17%). The CECreviewed all reported adverse events and determined
that 7.5% were possibly or deﬁnitely related to the
implantation or retrieval procedure and 5.0% were
possibly or deﬁnitely related to the ﬁlter (Table E1
[available online at www.jvir.org]). Death from
preexisting or concomitant medical conditions,
adjudicated by the CEC as unrelated to the device or
procedure, occurred in 21 patients.DISCUSSION
Through 30 days after retrieval or 2 years of follow-up
after placement of the Denali IVC ﬁlter, clinical success
was achieved in 95% of enrolled patients, corresponding
to a lower limit of the 95% CI of 91%, which surpassed
the SIR trial performance objective of greater than 80%.
Recurrent venous thromboembolic disease constituted
six of the 10 cases of clinical failure, with recurrent PE in
all six patients, corresponding to a PE rate of 3%, which
was below the established 5% threshold (6) and within
the 1%–6% range reported in previous IVC ﬁlter trials
(10–13). New or expanding DVT was detected in 26
patients (13%), which was also comparable to rates
reported in previous trials (10–13).
Device-related complications have been a challenging
obstacle for retrievable IVC ﬁlters (14), and were closely
evaluated during the DENALI trial. There was a low
rate of device complications detected in this study
compared with previous ﬁlter trials, despite the larger
patient cohort and longer follow-up period than previous
Table 3 . Filter Retrieval Data
Retrieval Variable
Retrieved Filters
(n ¼ 121)
Indwell time (d)
Mean  SD 200.8  156.9
Median 160
Range 5–736
Retrieval time (min)*
Mean  SD 23.1  17.77
Median 20
Range 4–118
Fluoroscopy time (min)
Mean  SD 6.3  8.52
Median 4.0
Range 1–69
IVC diameter (mm)
Mean  SD† 22.0  2.85
Median 21.1
Range 15.7–27.2
Filter retrieval access sites
Right jugular vein 121 (100)
Retrieval success
Retrieval attempts 124/200 (62)
Technical success of retrieval‡ 121/124 (97.6)
95% CI 93.1–99.5
Clinical success of retrieval§ 120/121 (99.2)
95% CI 95.5–100.0
Retrieval complication
Intimal injury and caval narrowing|| 1 (0.8)
Note–Values in parentheses are percentages.
CI ¼ conﬁdence interval; SD ¼ standard deviation.
*For all successful retrievals (n ¼ 121).
†Quantitatively measured by the core laboratory after retrieval.
‡One hundred twenty-one of 124 retrieval attempts were
successfully completed. In two cases, the operator was unable
to engage the ﬁlter apex with a snare. One device was
engaged with a snare but could not be removed.
§Successful technical retrieval of the ﬁlter without retrieval
complications.
||One patient experienced intimal injury and caval narrowing at
retrieval and was admitted to the hospital overnight for a
follow-up angiogram.
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ﬁlter studies between 1970 and 2014 (15) reported a 19%
prevalence of caval penetration, of which 5% of patients
experienced major complications. In the present study,
venographically detected IVC wall penetration by
ﬁlter struts was observed in 1.5% of patients at ﬁlter
implantation and 1.6% of patients at the time of ﬁlter
removal, and was asymptomatic in all cases. This rate
was comparatively low (16), despite possible inﬂation by
false-positive ﬁndings from venographic evaluation;
previous studies have shown better accuracy of CT
versus venography for distinguishing “tenting” from true
mural penetration (17), but CT was not used in the
present study. There were no instances of IVC ﬁlterfracture, migration, or ﬁlter tilt greater than 151 on
venography at ﬁlter removal. Asymptomatic IVC nar-
rowing following ﬁlter retrieval occurred in one patient,
who remained in stable condition and experienced no
subsequent sequelae. It is important to note that, al-
though no cases of ﬁlter fracture were detected in this
trial, one case of a Denali ﬁlter fracture, with symp-
tomatic strut fracture and embolization (18), has been
published since the interim DENALI study analysis (5).
Therefore, despite the favorable complication rate
observed in the DENALI trial, further postmarket
clinic studies evaluating the incidence and scope of
ﬁlter complications, such as the ongoing Predicting the
Safety and Effectiveness of Inferior Vena Cava Filters
trial (ClinicalTrials.gov ID NCT02381509), will be
extremely important to validate the ﬁndings of this trial.
FDA communications in 2010 and 2014 (19,20) em-
phasized the risk of adverse events of retrievable ﬁlters
that are left in situ for prolonged dwell times, highlighting
the necessity of vigilant clinical follow-up and ﬁlters that
accommodate safe, reliable retrieval after long-term
placement. Despite these communications, the rates of
ﬁlter retrieval in practice and in published articles have
remained modest: a retrospective study of 679 retrievable
ﬁlters placed at a level I trauma center (21) reported a
successful ﬁlter retrieval rate of only 8.5%. In the
DENALI trial, retrieval was attempted in 124 patients,
with success in 121 cases (98%) and failure in three (2%).
Two of the failures were related to inability of the
operators to engage the ﬁlter hook with a snare as a
result of anteroposterior angulation of the IVC. The third
case of retrieval failure was the result of high thrombus
burden in the ﬁlter not allowing the ﬁlter to be collapsed.
Filter strut incorporation and ﬁlter hook embedment in
the IVC wall, which are among the most common causes
of retrieval failure (22), were not seen in any cases.
Adjunctive ﬁlter retrieval techniques with the use of
loop snares or endobronchial forceps, which have demon-
strated successful application in challenging ﬁlter retrieval
cases (23), were not used in the DENALI study, and
could have potentially further augmented the retrieval
success rate. The 24-month follow-up period allowed
evaluation of retrieval outcomes at longer dwell times
(maximum of 736 d) than previous ﬁlter trials, which used
follow-up periods of 12 months or shorter (10–13,24–26).
The feasibility and safety of retrieval at these longer time
points are advantageous characteristics that may contri-
bute to overall improved ﬁlter retrieval rates for the
Denali ﬁlter. Despite the long-term retrievals possible with
the Denali ﬁlter, it remains imperative that physicians
placing this or any IVC ﬁlter follow their patient closely
and remove the ﬁlter as soon as it is no longer needed.
Several limitations must be considered when interpret-
ing the DENALI trial, including bias from the non-
randomized single-arm design of 200 patients. As
acknowledged in other similar trials (10–13,24–26),
the rate of recurrent PE may have been underestimated,
Figure 2. Filter indwell time (the duration in days between the initial implantation procedure and ﬁlter retrieval) for the 121 successfully
retrieved ﬁlters. The mean indwell time was 200.8 days  156.9 (range, 5–736 d). A total of 46.3% of ﬁlters were retrieved after dwell
times 4 180 days.
Table 4 . Overall Clinical Experience
Variable Incidence 95% CI
Recurrent PE* 6/200 (3.0) 1.1–6.4
DVT 26/200 (13.0) 8.7–18.5
New† 18/200 (9.0) –
Worsening‡ 8/200 (4.0) –
Filter fracture, migration, penetration, tilt§
Fracture 0/184 0.0–2.0
Migration (4 2 cm) 0/184 0.0–2.0
Penetration at placement 3/200 (1.5) 0.3–4.3
Penetration at retrieval 2/121 (1.6) 0.2–5.7
Tilt 4 151 0/200 0.0–1.8
Note–Values in parentheses are percentages.
DVT ¼ deep vein thrombosis; PE ¼ pulmonary embolism.
*Seven recurrent PEs in six patients: clinical diagnosis of
recurrent PE was conﬁrmed by pulmonary arteriography,
cross-sectional imaging, or altered ventilation/perfusion lung
scan or at autopsy.
†New DVT, based on imaging, in patients who had no DVT at
baseline.
‡Extension of existing DVT, based on imaging, to a new
venous segment in patients who had DVT at baseline.
§Core laboratory evaluated all implant, follow-up, and retrieval
images.
Volume 27 ’ Number 10 ’ October ’ 2016 1537as asymptomatic patients did not undergo imaging
evaluation. The patient follow-up that occurred at 12,
18, and 24 months was via phone-call interviews with the
patient and therefore did not involve a physical exami-
nation or imaging. This limitation causes an inherent
underreporting of nonsymptomatic ﬁlter complications
that would not be reported over the phone by the patient
or cause the patient to present for medical attentionbefore the phone interviews. Although no fractures or
embolizations were detected in this trial, it is a relatively
small study compared with the large number of ﬁlters
placed clinically since the device received FDA appro-
val. As mentioned earlier, there has been a published
case of a Denali ﬁlter fracture and strut embolization
(18), and additional cases will likely present as the
number and dwell times of implanted Denali ﬁlters
increase greatly relative to the 200 patients in this trial.
This emphasizes the critical need and importance of
further publication of postmarket clinical studies to fully
determine the safety proﬁle for this and similar medical
devices. In addition, imaging of the ﬁlter was not
routinely performed on all patients at 2 years, so the
rate of nonsymptomatic ﬁlter complications such as
fracture, migration, and perforation and DVT could
have been further underestimated. Further limitations
include the fact that CT scans were not used to evaluate
for strut penetration and the fact that ﬁlter retrieval was
not attempted in 76 patients.
The DENALI trial demonstrates clinical success in
placement and retrieval of the Denali IVC ﬁlter. Further
data from ongoing clinical use of this ﬁlter and data from
the Predicting the Safety and Effectiveness of Inferior
Vena Cava Filters trial will provide important additions
to this experience. The present trial demonstrated reliable
and safe ﬁlter retrieval at prolonged dwell times, which
suggests an opportunity for improved ﬁlter retrieval rates.ACKNOWLEDGMENTS
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Table E1 . Adverse Events by System Organ Class
Category Patients with Z 1 Event
Adverse Events*
Device-Related Procedure-Related
All patients, all adverse events† 160 (80.0) 10 (5.0) 15 (7.5)
Blood and lymphatic system disorders 33 (16.5) 0 0
Cardiac disorders 33 (16.5) 0 0
Congenital, familial, and genetic disorders 2 (1.0) 0 0
Ear and labyrinth disorders 1 (0.5) 0 0
Endocrine disorders 1 (0.5) 0 0
Gastrointestinal disorders 68 (34.0) 2 (1.0) 0
Eye disorders 6 (3.0) 0 0
General disorders/administration-site conditions 48 (24.0) 2 (1.0) 2 (1.0)
Hepatobiliary disorders 8 (4.0) 0 0
Immune system disorders 3 (1.5) 0 0
Infections and infestations 65 (32.5) 0 0
Injury, poisoning, and procedural complications 33 (16.5) 1 (0.5) 4 (2.0)
Investigations 16 (8.0) 0 0
Metabolism and nutrition disorders 29 (14.5) 0 0
Musculoskeletal and connective-tissue disorders 56 (28.0) 2 (1.0) 7 (3.5)
Neoplasms (benign, malignant, and unspeciﬁed)‡ 16 (8.0) 0 0
Nervous system disorders 37 (18.5) 0 0
Psychiatric disorders 8 (4.0) 0 0
Renal and urinary disorders 26 (13.0) 0 0
Reproductive system and breast disorders 6 (3.0) 0 0
Respiratory, thoracic and mediastinal disorders 33 (16.5) 1 (0.5) 0
Skin and subcutaneous tissue disorders 18 (9.0) 0 1 (0.5)
Vascular disorders 47 (23.5) 3 (1.5) 1 (0.5)
Note–Adverse events are listed by Medical Dictionary for Regulatory Activities preferred terms. Values in parentheses are
percentages.
*AEs were adjudicated and classiﬁed by the independent Clinical Events Committee.
†Denominator is 200 enrolled patients. Some patients had adverse events in one or more category.
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